|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Tscan Therapeutics, Inc. (TCRX) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
43,550,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile TScan Therapeutics is a clinical-stage biopharmaceutical company focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. Co.'s proprietary platform is designed to: discover anti-cancer TCRs from patients with exceptional responses to immunotherapy; discover TCRs that recognize clinically validated targets; identify off-targets of TCRs to eliminate candidates; and manufacture TCR-T therapies using Co.'s T-Integrate technology. The central elements of Co.'s platform that differentiate it from other cell therapy companies are TargetScan, ReceptorScan, SafetyScan, ImmunoBank and T-Integrate.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
34,147 |
72,027 |
1,462,819 |
Total Buy Value |
$0 |
$167,856 |
$267,420 |
$2,925,612 |
Total People Bought |
0 |
2 |
2 |
5 |
Total Buy Transactions |
0 |
3 |
4 |
9 |
Total Shares Sold |
0 |
0 |
25,400 |
25,400 |
Total Sell Value |
$0 |
$0 |
$63,953 |
$63,953 |
Total People Sold |
0 |
0 |
1 |
1 |
Total Sell Transactions |
0 |
0 |
2 |
2 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Barberich Timothy J |
|
|
2023-12-19 |
4 |
B |
$4.97 |
$1,575 |
D/D |
317 |
67,027 |
0.01 |
- |
|
Barberich Timothy J |
|
|
2023-12-18 |
4 |
B |
$4.89 |
$140,881 |
D/D |
28,830 |
66,710 |
0.01 |
- |
|
Klencke Barbara |
|
|
2023-12-14 |
4 |
B |
$5.08 |
$25,400 |
D/D |
5,000 |
30,000 |
0.01 |
- |
|
Dworak Leiden |
Chief Accounting Officer |
|
2023-07-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,692 |
|
- |
|
Barberich Timothy J |
Director |
|
2023-06-02 |
4 |
B |
$2.63 |
$99,564 |
D/D |
37,880 |
37,880 |
2.39 |
- |
|
Nichols Weston |
10% Owner |
|
2023-05-31 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,250,000 |
|
- |
|
Nichols Weston |
10% Owner |
|
2023-05-31 |
4 |
S |
$2.51 |
$38,805 |
I/I |
(15,400) |
5,224,600 |
|
- |
|
Nichols Weston |
10% Owner |
|
2023-05-31 |
4 |
S |
$2.51 |
$25,148 |
I/I |
(10,000) |
5,240,000 |
|
- |
|
Ecor1 Capital, Llc |
10% Owner |
|
2023-05-26 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,000,000 |
|
- |
|
Klencke Barbara |
Director |
|
2023-04-06 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
25,000 |
|
- |
|
Klencke Barbara |
Director |
|
2023-04-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
25,000 |
|
- |
|
Silver Brian M. |
Chief Financial Officer |
|
2022-12-28 |
4 |
B |
$1.56 |
$4,941 |
D/D |
3,158 |
32,885 |
2.66 |
- |
|
Silver Brian M. |
Chief Financial Officer |
|
2022-12-27 |
4 |
B |
$1.50 |
$4,276 |
D/D |
2,842 |
29,727 |
2.66 |
- |
|
Southwell David P |
Chief Executive Officer |
|
2022-05-18 |
4 |
B |
$3.55 |
$89,821 |
D/D |
25,000 |
171,569 |
2.81 |
- |
|
Baker Brothers Life Sciences Lp |
Director |
|
2022-05-11 |
4 |
B |
$1.99 |
$51,350 |
I/I |
25,865 |
2,528,583 |
2.25 |
- |
|
Baker Brothers Life Sciences Lp |
Director |
|
2022-05-10 |
4 |
B |
$1.70 |
$2,507,804 |
I/I |
1,333,927 |
2,505,600 |
2.25 |
- |
|
Silver Brian M. |
Chief Financial Officer |
|
2022-03-24 |
4 |
B |
$3.40 |
$50,982 |
D/D |
15,000 |
26,885 |
2.74 |
- |
|
Southwell David P |
Chief Executive Officer |
|
2021-12-23 |
4 |
OE |
$1.97 |
$95,880 |
D/D |
48,670 |
146,569 |
|
- |
|
Zdraveski Zoran |
Chief Legal Officer |
|
2021-09-23 |
4 |
B |
$7.48 |
$35,255 |
D/D |
4,716 |
4,716 |
2.74 |
- |
|
Silver Brian M. |
Chief Financial Officer |
|
2021-09-21 |
4 |
B |
$6.32 |
$31,585 |
D/D |
5,000 |
11,885 |
2.74 |
- |
|
Macbeath Gavin |
Chief Scientific Officer |
|
2021-09-21 |
4 |
B |
$6.19 |
$353 |
D/D |
57 |
49,767 |
2.66 |
- |
|
Macbeath Gavin |
Chief Scientific Officer |
|
2021-09-20 |
4 |
B |
$6.22 |
$30,744 |
D/D |
4,943 |
49,710 |
2.74 |
- |
|
Silver Brian M. |
Chief Financial Officer |
|
2021-09-09 |
4 |
B |
$8.48 |
$49,925 |
D/D |
5,885 |
6,885 |
2.74 |
- |
|
Southwell David P |
Chief Executive Officer |
|
2021-09-08 |
4 |
B |
$8.73 |
$96,066 |
D/D |
11,000 |
97,899 |
2.81 |
- |
|
Desmarais William |
Chief Business Officer |
|
2021-08-27 |
4 |
B |
$9.08 |
$22,708 |
D/D |
2,500 |
2,500 |
2.74 |
- |
|
30 Records found
|
|
Page 1 of 2 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|